Calcitonin Gene Related Peptide Type 1 Receptor drugs in development, 2023
The report also covers products from therapy areas such as Central Nervous System, Dermatology, Undisclosed, and Cardiovascular which include the indications Migraine, Cluster Headache Syndrome (Cluster Headache), Diabetic Foot Ulcers, Rosacea, Unspecified, and Resistant Hypertension. It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Calcitonin Gene Related Peptide Type 1 Receptor pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, and Discovery stages are 4, and 2 respectively.
Calcitonin Gene Related Peptide Type 1 Receptor overview
Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
For a complete picture of Calcitonin Gene Related Peptide Type 1 Receptor’s drug pipeline, buy the report here.
Source link
#Calcitonin #Gene #Related #Peptide #Type #Receptor #drugs #development